Clinical Trials Directory

Trials / Completed

CompletedNCT05498337

Vital Pulp Therapy With Different Materials for Young Permanent Teeth

Clinical Evaluation of Different Treatment Modalities for Vital Pulp of Immature Permanent Molars

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Mansoura University · Academic / Other
Sex
All
Age
7 Years – 9 Years
Healthy volunteers
Accepted

Summary

This study will be conducted to: Evaluate clinically and radiographically apexogenesis in immature permanent molars using: 1. Calcium Hydroxide. 2. MTA. 3. Laser. 4. Laser combined with MTA.

Detailed description

Calcium Hydroxide has been the most commonly utilized pulpotomy agent for vital pulp therapy. It is the earliest medicament employed in pulpotomy that possesses the ability to stimulate tertiary dentinogenesis. This is attributed to its high alkalinity after mixing with water. Calcium hydroxide has a high pH, and its dental use relates chiefly to its ability to stimulate mineralization and also to its antibacterial property. Biocompatibility and sealing ability are the most important properties, which account for optimal healing response in vital pulp therapy. Unlike conventional materials, MTA has low solubility and maintains its physical integrity after placement. It has several desirable characteristics in terms of biocompatibility, bioactivity, hydrophilicity, radiopacity, sealing ability and low solubility. Diode laser in a young permanent tooth with traumatically exposed pulp has proved to be an effective technique for Pulpotomy in an immature tooth. Therefore, the use of soft-tissue diode lasers can influence the treatment outcome and should be seen as a predicable tool for vital pulp therapy.

Conditions

Interventions

TypeNameDescription
OTHERcalcium hydroxideDental pulp medicament material
OTHERMTADental pulp medicament material
DEVICEDiode LaserDevice used in pulp therapy

Timeline

Start date
2022-09-01
Primary completion
2023-09-30
Completion
2024-04-01
First posted
2022-08-12
Last updated
2025-10-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05498337. Inclusion in this directory is not an endorsement.